CVD Risk Estimator Plus vs COAPT Risk Score

This clinical decision-support app is intended for use by healthcare professionals and unifies two cardiovascular prevention tools: the 2013 ACC/AHA Pooled Cohort Equations (previously known as the ASCVD Risk Estimator) and the American Heart Association’s PREVENT™ Calculator. Combining traditional ASCVD risk modeling with modern cardiovascular-kidney-metabolic (CKM)-inclusive risk equations, CVD Risk Estimator Plus supports comprehensive, personalized cardiovascular disease (CVD) risk assessment and clinician-guided decision-making. The results and recommendations provided by this application are intended to inform but do not replace clinical judgment. Therapeutic options should be individualized and determined after discussion between the patient and their care provider. CVD Risk Estimator Plus computes risk estimates using: • 2013 ASCVD Pooled Cohort Equations (PCE), which calculate 10-year and lifetime risk of atherosclerotic cardiovascular disease using age, sex, race, blood pressure, cholesterol profile, diabetes status, and smoking status. • 2023 PREVENT™ Equations, which estimate 10- and 30-year risk for total CVD, ASCVD, and heart failure (HF), incorporating kidney and metabolic health measures such as BMI and estimated glomerular filtration rate (eGFR), and supporting optional predictors including urine albumin creatinine ratio (UACR), hemoglobin A1c (HbA1c), and social deprivation index (SDI). Clinicians can toggle between Pooled Cohort and PREVENT™ risk trajectories to support guideline-aligned prevention discussions. This clinical decision support app provides: • Risk category classification (low, borderline, intermediate, high). • Personalized guidance informed by published guidelines, including statin therapy considerations, lifestyle interventions, and risk-enhancing clinical factors. • Export functionality supporting print and email of results for documentation and patient communication. • Resources page with related tools and informational materials for clinicians and patients, including links to source guidelines and reference documents.

For educational purposes and for use by medical professionals only. For patients with severe functional mitral regurgitation and symptomatic heart failure (left ventricular ejection fraction between 20-50%) despite best medical therapy. The COAPT Risk Score is a simple risk prediction tool created by combining clinical and echocardiographic variables in patients with heart failure (HF) and moderate-to-severe or severe functional mitral regurgitation (FMR) who remain symptomatic despite maximally tolerated guideline directed medical therapy (GDMT). The COAPT Risk Score provides valuable prognostic information regarding the 2-year risk of death and/or heart failure hospitalization (HFH). The score is derived from the COAPT trial population of patients with HF and moderate-to-severe or severe FMR randomized to treatment with either transcatheter edge-to-edge repair (TEER) with MitraClip plus GDMT or GDMT alone. We can incorporate TEER in the risk score and provide updated 2-year risk of death and/or HFH which can serve as a valuable shared decision-making tool for patients and physicians as well as heart teams while deciding about TEER. Created by a team of subject-matter experts including: the director of The Mount Sinai Hospital cardiac cath lab Dr. Kini, Director of Clinical and Interventional Cardiology at the Mount Sinai Health System Dr Sharma, the Mount Sinai Hospital Surgical Director Dr. Tang, COAPT Principal Investigator Dr. Stone, and COAPT Risk Score publication author Dr. Shah.